| 44.01 Delayed Data As of 4:00pm ET |  -0.39 / -0.88%Today’s Change | 33.20 Today|||52-Week Range 46.47 | +21.51% Year-to-Date |
| Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know Dec 10 / Zacks.com - Paid Partner Content | Pfizer (PFE) Stock Moves -1.78%: What You Should Know Dec 04 / Zacks.com - Paid Partner Content |
| Stocks Close Marginally Higher Monday Dec 10 / GuruFocus News - Paid Partner Content | AbbVie Settles With Pfizer for Humira Biosimilar in U.S. Dec 03 / Zacks.com - Paid Partner Content |
| Phil Fisher: When to Buy Stocks Dec 06 / GuruFocus News - Paid Partner Content | Dow 30 Stock Roundup: BA's $383M Modification Contract, MSFT's Army Contract Nov 30 / Zacks.com - Paid Partner Content |
| Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study Dec 06 / Zacks.com - Paid Partner Content | Pfizer (PFE) Up 4.3% Since Last Earnings Report: Can It Continue? Nov 29 / Zacks.com - Paid Partner Content |
| Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx Dec 06 / Zacks.com - Paid Partner Content | Roche (RHHBY) to Acquire Jecure and Enter the NASH Space Nov 29 / Zacks.com - Paid Partner Content |
| Previous close | 44.40 |
| Today’s open | 44.08 |
| Day’s range | 43.57 - 44.51 |
| Volume | 22,656,035 |
| Average volume (3 months) | 21,958,800 |
| Market cap | $250.0B |
| Earnings growth (last year) | +202.42% |
| Earnings growth (this year) | +13.46% |
| Earnings growth (next 5 years) | +7.40% |
| Revenue growth (last year) | -0.53% |
| P/E ratio | 11.1 |
| Price/Sales | 4.18 |
| Price/Book | 3.61 |
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | +0.32 | +0.37% |
| MRKMerck | -0.31 | -0.40% |
| ABBVAbbVie | +0.56 | +0.64% |
| ABTAbbott Laboratories | +0.92 | +1.30% |
| Next reporting date | January 29, 2019 |
| EPS forecast (this quarter) | $0.65 |
| Annual revenue (last year) | $52.5B |
| Annual profit (last year) | $21.3B |
| Net profit margin | 40.55% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman & Chief Executive Officer Ian C. Read |
Chief Operating Officer & Director Albert Bourla |
Corporate headquarters New York, New York |
